IDEAS home Printed from https://ideas.repec.org/a/nas/journl/v115y2018p12911-12919.html
   My bibliography  Save this article

Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR

Author

Listed:
  • J. P. Sevilla

    (Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA 02115; Life Sciences Group, Data for Decisions, LLC, Waltham, MA 02451)

  • David E. Bloom

    (Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA 02115)

  • Daniel Cadarette

    (Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA 02115)

  • Mark Jit

    (Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Modeling and Economics Unit, Public Health England, London NW9 5EQ, United Kingdom)

  • Marc Lipsitch

    (Center for Communicable Disease Dynamics, Harvard T.H. Chan School of Public Health, Boston, MA 02115; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115)

Abstract

We discuss the need to make economic evaluations of vaccines antimicrobial resistance (AMR)-sensitive and ways to do so. Such AMR-sensitive evaluations can play a role in value-for-money comparisons of different vaccines within a national immunization program, or in comparisons of vaccine-centric and non-vaccine-centric technologies within an anti-AMR program. In general terms, incremental cost-effectiveness ratios and rates of return and their associated decision rules are unaltered by consideration of AMR-related value. The decision metrics need to have their various health, cost, and socioeconomic terms disaggregated into resistance-related subcategories, which in turn have to be measured carefully before they are reaggregated. The fundamental scientific challenges lie primarily in quantifying the causal impact of health technologies on resistance-related health outcomes, and secondarily in ascertaining the economic value of those outcomes. We emphasize the importance of evaluating vaccines in the context of other potentially complementary and substitutable nonvaccine technologies. Complementarity implies that optimal spending on each set of interventions is positive, and substitutability implies that the ratio of spending will depend on relative value for money. We exemplify this general point through a qualitative discussion of the complementarities and (especially the) substitutability between pneumococcal conjugate vaccines and antimicrobial stewardship and between research and development (R&D) of a gonorrhea vaccine versus R&D of a gonorrhea antibiotic. We propose a roadmap for future work, which includes quantifying the causal effects of vaccination and other health technologies on short-term and long-term resistance-related outcomes, measuring the health-sector costs and broader socioeconomic consequences of resistance-related mortality and morbidity, and evaluating vaccines in the context of nonvaccine complements and substitutes.

Suggested Citation

  • J. P. Sevilla & David E. Bloom & Daniel Cadarette & Mark Jit & Marc Lipsitch, 2018. "Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR," Proceedings of the National Academy of Sciences, Proceedings of the National Academy of Sciences, vol. 115(51), pages 12911-12919, December.
  • Handle: RePEc:nas:journl:v:115:y:2018:p:12911-12919
    as

    Download full text from publisher

    File URL: http://www.pnas.org/content/115/51/12911.full
    Download Restriction: no
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. V. Srinivasan & David E. Bloom & Alex Khoury, 2022. "Forecasting the Incremental Value to Society Created by a Class of New Prescription Drugs: A Proposed Methodology and Its Application to Treating Chronic Hepatitis C in India," Applied Health Economics and Health Policy, Springer, vol. 20(3), pages 371-381, May.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nas:journl:v:115:y:2018:p:12911-12919. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Eric Cain (email available below). General contact details of provider: http://www.pnas.org/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.